Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.58 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | PPID | Q08752 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1165214 | 0.88 | EGLN3 (0.59) | EGLN3EGLN1HPGDPPIDRXFP1 | |
| SCHEMBL1165598 | 0.87 | EGLN3 (0.55) | EGLN3EGLN1HPGDPPIDRXFP1 | |
| SCHEMBL1079849 | 0.86 | EGLN3 (0.77) | EGLN3EGLN1NR1H4 | |
| SCHEMBL1165430 | 0.82 | EGLN3 (0.62) | EGLN3EGLN1HPGDPPIDRXFP1 | |
| SCHEMBL1080231 | 0.78 | EGLN3 (0.55) | EGLN3EGLN1HPGDPOLBNR1H4 | |
| SCHEMBL1081707 | 0.76 | EGLN3 (0.74) | EGLN3EGLN1NR1H4L3MBTL1KDM4E | |
| SCHEMBL1082016 | 0.76 | EGLN3 (0.60) | EGLN3EGLN1ALDH1A1TP53 | |
| SCHEMBL1080932 | 0.75 | EGLN3 (0.75) | EGLN3EGLN1NR1H4 | |
| SCHEMBL1080635 | 0.74 | EGLN3 (0.71) | EGLN3EGLN1NR1H4L3MBTL1 | |
| SCHEMBL13620662 | 0.74 | EGLN3 (1.00) | EGLN3EGLN1HPGDPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxo Smith Kline LLC., a corporation | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN1 6/4885HPGD 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.